1. Home
  2. RDNW vs ELTX Comparison

RDNW vs ELTX Comparison

Compare RDNW & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDNW

RideNow Group Inc.

HOLD

Current Price

$7.16

Market Cap

221.9M

Sector

Technology

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$10.80

Market Cap

209.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDNW
ELTX
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.9M
209.9M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RDNW
ELTX
Price
$7.16
$10.80
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$6.50
$18.00
AVG Volume (30 Days)
48.7K
112.1K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
$9.01
N/A
Revenue Next Year
$6.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.98
$4.89
52 Week High
$7.20
$14.93

Technical Indicators

Market Signals
Indicator
RDNW
ELTX
Relative Strength Index (RSI) 62.57 45.49
Support Level $5.64 $9.85
Resistance Level N/A $11.23
Average True Range (ATR) 0.36 0.96
MACD 0.03 -0.07
Stochastic Oscillator 86.32 22.11

Price Performance

Historical Comparison
RDNW
ELTX

About RDNW RideNow Group Inc.

RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Share on Social Networks: